



(11)

EP 2 340 254 B8

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
21.05.2014 Bulletin 2014/21

(45) Date of publication and mention
of the grant of the patent:
02.04.2014 Bulletin 2014/14

(21) Application number: **09813797.9**

(22) Date of filing: **15.09.2009**

(51) Int Cl.:
A61K 31/437^(2006.01) A61K 31/444^(2006.01)
A61P 25/08^(2006.01)

(86) International application number:
PCT/US2009/056988

(87) International publication number:
WO 2010/031054 (18.03.2010 Gazette 2010/11)

(54) **COMPOSITIONS AND METHODS FOR TREATING EPILEPSY**

ZUSAMMENSETZUNGEN UND VERFAHREN ZUR BEHANDLUNG VON EPILEPSIE

COMPOSITIONS ET PROCÉDÉS POUR TRAITER L'ÉPILEPSIE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL
PT RO SE SI SK SM TR

(30) Priority: **15.09.2008 US 96940 P**
02.06.2009 US 183209 P

(43) Date of publication of application:
06.07.2011 Bulletin 2011/27

(73) Proprietor: **Biovista, Inc.**
Charlottesville, VA 22903 (US)

(72) Inventors:
• **DEFTEREOS, Spyros**
GR-15342 Athens (GR)
• **PERSIDIS, Andreas**
GR-16673 Athens (GR)

(74) Representative: **Elsy, David**
Withers & Rogers LLP
4 More London Riverside
London SE1 2AU (GB)

(56) References cited:
US-A1- 2003 171 270 US-A1- 2004 228 923

US-A1- 2006 154 968 US-A1- 2007 150 024
US-A1- 2008 108 574

- **BACHURIN S ET AL: "Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES JUN 2001,, vol. 939, 1 June 2001 (2001-06-01), pages 425-435, XP002478538,**
- **DECKERS C L P ET AL: "SELECTION OF ANTIEPILEPTIC DRUG POLYTHERAPY BASED ON MECHANISMS OF ACTION: THE EVIDENCE REVIEWED", EPILEPSIA, RAVEN PRESS LTD, NEW YORK, US, vol. 41, no. 11, 1 January 2000 (2000-01-01), pages 1364-1374, XP009035157, ISSN: 0013-9580, DOI: 10.1111/J.1528-1157.2000.TB00111.X**
- **MURAKI T ET AL: "Inhibition of benzodiazepine and GABA receptor binding by amino-gamma-carbolines and other amino acid pyrolysate mutagens", EUROPEAN JOURNAL OF PHARMACOLOGY, ELSEVIER SCIENCE, NL, vol. 98, no. 1, 10 February 1984 (1984-02-10), pages 35-44, XP023749611, ISSN: 0014-2999, DOI: 10.1016/0014-2999(84)90106-7 [retrieved on 1984-02-10]**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 340 254 B8

- SARKISIAN M R: "Overview of the Current Animal models for Human Seizure and Epileptic Disorders", EPILEPSY & BEHAVIOR, vol. 2, 1 January 2001 (2001-01-01), pages 201-216,